Posted by pseudonym on November 25, 2004, at 13:18:56
In reply to Re: Good news: Dov's ocinaplon in phase III, posted by rvanson on November 25, 2004, at 5:22:40
rvanson, I hear you on the elevated liver enzyme issue. As I recall, that issue came from one patient in the phase II trial, it was not widespread. But anyway, that's part of the point of the phase III trial, to test liver enzymes, along with efficacy. If liver enzymes are a problem, then the drug will be rejected period. If not, then we have something to look forward too.
The reason this is exciting to me is the mechanism of action - Ocinaplon is not a "me-too" compound like Cymbalta. Closely associated with with Ocinaplon is Indiplon, which is licensed via Pfizer/Neurocrine. Indiplon compound targets the GABA-A receptors responsible for sedation. If you want muscle-incoordination, they can probably build you a drug for that too:) It depends on which subtype you target.
poster:pseudonym
thread:419216
URL: http://www.dr-bob.org/babble/20041123/msgs/420192.html